EMERYVILLE, Calif.--(EON: Enhanced Online News)--KineMed, Inc. (www.kinemed.com) today announced that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded the company a Phase I SBIR (Small Business Innovation Research) contract to develop biomarkers for the detection of early myocardial fibrosis. Biomarkers for myocardial fibrosis will guide disease interventions that block the progression of this disease which is risk factor for heart failure and arrhythmias.
“We are gratified to acknowledge this award from the NIH SBIR program to advance KineMed’s development of non-invasive biomarkers for myocardial fibrosis”
The goal of this $225,000 contract is to significantly advance non-invasive methods to detect, and monitor myocardial fibrosis in vivo. Early detection of myocardial fibrosis is essential to the development of effective ways to diagnose, treat, and prevent fibrotic cardiac disorders. Current methods of detection are either invasive biopsy-based tests or are unable to detect fibrogenesis in its early stages.
"We are gratified to acknowledge this award from the NIH SBIR program to advance KineMed’s development of non-invasive biomarkers for myocardial fibrosis," said Dr. Scott Turner, Executive Vice-President, R&D at KineMed. “KineMed’s Dynamic Proteomics technology allows the discovery and development of novel protein biomarker targets based on changes in their synthesis and breakdown rates, thereby overcoming many of the limitations of static, conventional proteomic measurements. When applied to blood proteins, Dynamic Proteomics has led to the discovery of non-invasive markers of the protein synthesis that correlate directly to the fibrotic process in remodeling heart tissue, creating a “virtual biopsy” of intra-cardiac pathogenic processes from patient blood samples.”
“Under this grant, KineMed will identify and validate novel plasma biomarkers of myocardial fibrosis that will be tested in humans, with the goal of developing clinical biomarkers and diagnostic tests. A simple blood-based measurement to accurately assess myocardial fibrogenesis would be a significant advance in the ability to develop effective therapeutics, identify appropriate patients for treatments, and monitor response to therapy in clinical trials as well as routine medical care. We thank the NIH and are proud to be collaborating on an initiative that can potentially bring benefit to millions of Americans threatened by fibrotic disease.”
About KineMed, Inc.
KineMed is a commercial-stage company with a biomarker platform technology that is potentially transformative for drug development, personalized medicine, and wellness monitoring. KineMed's diagnostic biomarkers provide personal biology information to guide therapeutic decisions. KineMed’s biomarker platform provides dynamic molecular information through a proprietary mass spectrometric platform, representing the missing link between individuals and optimal health-related products and services. Active initiatives include prescription and non-prescription FDA-cleared diagnostic tests for personalized medicine and the next generation of drug development. These programs provide near-, mid-, and long-term revenues for KineMed from patients, payors, drug developers, and corporate partnerships.
KineMed has developed the first practically useful systems biology technology that can be used directly in humans, with applications not only in drug discovery and development, but also in clinical diagnosis, personalized medicine and therapeutic monitoring, including OTC wellness decisions. KineMed has three programs based on KineMed’s personal biology information: Rx, Dx, and Dx/Rx:
Drug discovery and development (“Rx”)
- Co-development partnerships with Pharma and Biotech to improve drug development efficiency, through R&D deals, milestone-based collaborations, and Center-of-Excellence programs
Prescription and non-prescription diagnostic tests (“Dx”)
- FDA-cleared diagnostic tests providing personalized information about key biologic processes, to allow precision medical management based on disease subtype and activity and to enable informed wellness decisions based on what is needed and what is working in each person
Diagnostic test/drug pairings (“Dx/Rx”)
- Diagnostic tests that are paired with therapeutic agents, to develop in-house drug candidates and invigorate underperforming drugs and nutriceuticals
KineMed’s biomarkers are fully translatable from animal to man across pre-clinical and clinical phases of development. This platform applies to diagnosis and management across the spectrum of diseases, including conditions involving fibrosis, neurodegeneration, muscle loss, metabolic cardiovascular or dermatologic disorders and cancer, as well as consumer wellness.
Over the past few years, KineMed has changed both textbook thought about diseases and the development path of several drug candidates. Notable accomplishments include:
- Transforming the pathogenic model of chronic lymphocytic leukemia (CLL)
- Developing the first blood-based biomarker of tissue fibrogenesis in humans
- Generating the first accurate non-invasive laboratory biomarkers of muscle mass and muscle quality in humans
- Creating the first diagnostic tests of disease-modifying processes in a neurodegenerative disease (Parkinson’s disease)
- Developing a “tachometer” of reverse cholesterol transport and metrics of plasma lipid dynamics
- Identifying new, secondary indications for drug candidates in Pharma pipelines
- Identifying new targets for drug development in several important diseases
For more information about KineMed, please visit: www.kinemed.com